Re-trafficking of herg reverses long QT syndrome 2 phenotype in human iPS-derived cardiomyocytes
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Oct 24, 2017
Grant Date -
Feb 4, 2016
app pub date -
Mar 14, 2014
filing date -
Mar 15, 2013
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present invention relates to generating hiPSC-derived cardiomyocytes and embryoid bodies that recapitulate the disease phenotype of Long QT Syndrome and their use in developing pharmacological treatments thereof. The present invention also includes the use of a compound which inhibits the ubiquitin-proteasome pathway for the preparation of a medicament for the prophylaxis or treatment of a disease associated with prolonged ventricular repolarization (cardiac arrhythmia) caused by one or more mutations in the amino acid sequence of the hERG potassium channel.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully